Andere Sprachen Cellectar Biosciences, Inc.

Aktien

A3DQSD

US15117F8077

CLRB

Realtime-Estimate Cboe BZX Andere Börsenplätze 18:14:01 27.06.2024			% 5 Tage	% 1. Jan.
2.535 ^USD	-12.28%		-10.65%	-9.68%

29.05.	Cellectar Biosciences, Inc. und das City of Hope Cancer Center vereinbaren Zusammenarbeit zur Evaluierung von Iopofosine I 131 bei Mycosis fungoides	CI
14.05.	Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape	12:40
Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides	29.05.
Cellectar Biosciences, Inc. and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis fungoides	29.05.
Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update	14.05.
Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day	08.05.
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024	07.05.
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update	27.03.
Cellectar Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024	20.03.
Cellectar Biosciences : Corporate Presentation - March 2024	18.03.
Cellectar Biosciences to Present at the 36th Annual Roth Conference	14.03.
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer	04.03.
Cellectar Biosciences, Inc. Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer	04.03.
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	07.02.
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study	30.01.
Cellectar Biosciences, Inc. Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1B Clinical Study	30.01.
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million	25.01.
Cellectar Biosciences Reports Complete Central Nervous System Clearance in Relapsed, Refractory Waldenstrom's Macroglobulinemia Patient	23.01.
Sector Update: Health Care Stocks Advance Late Afternoon	22.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Cellectar Biosciences, Inc.

Aktien

A3DQSD

US15117F8077

CLRB

Andere Sprachen

Filter